Fujita Health University Favipiravir Trial Evidences no Statistically Conclusive Benefit to COVID-19 Patients: A Question Mark for Favipiravir?

Fujita Health University concluded a clinical study of the antiviral drug Avigan and report it has failed to demonstrate a clear efficacy in treating SARS-CoV-2 patients in the early stage of the infection. The Japanese university reports that the delta between those...

Pin It on Pinterest